Merck & Co., Inc. $MRK Stock Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 5.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,254,739 shares of the company’s stock after selling 119,254 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Merck & Co., Inc. were worth $327,636,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in MRK. Bullseye Investment Management LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $27,000. Horizons Wealth Management bought a new stake in Merck & Co., Inc. during the third quarter worth approximately $30,000. Graney & King LLC grew its holdings in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in Merck & Co., Inc. during the second quarter valued at approximately $41,000. Finally, Evergreen Advisors LLC acquired a new position in Merck & Co., Inc. during the first quarter valued at approximately $43,000. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the subject of a number of analyst reports. TD Cowen boosted their price objective on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, September 23rd. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, October 5th. Scotiabank lifted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a report on Tuesday, September 29th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Jefferies Financial Group upped their price objective on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. Stock Up 3.2%

Shares of MRK stock opened at $148.19 on Wednesday. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock has a fifty day moving average price of $146.22 and a 200 day moving average price of $129.67. The stock has a market cap of $365.62 billion, a P/E ratio of 118.55, a price-to-earnings-growth ratio of 6.64 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity

In related news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last ninety days. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.